Bristol Myers: The Beat Was Priced In, But the Guidance Reset the Game

The headline numbers were solid. Bristol Myers Squibb posted fourth-quarter adjusted earnings of , . , . For the full year, , .

On paper, that's a clear beat. But in the game of expectations, the real story is often what follows the print. In this case, the beat was largely expected. The whisper number had already baked in a strong quarter, leaving little room for a "surprise" pop. The market's focus quickly shifted to what management had to say about the future. That's where the setup for a reset began.

The Guidance Reset: Raising the Bar for 2026

The beat in the fourth quarter was expected. The real move came with the forward view. Bristol Myers Squibb didn't just meet the whisper number for 2026; it reset the entire baseline. The company's new full-year guidance is a clear upgrade, signaling that management sees a more favorable path than the market had priced in.

The numbers are decisive. For 2026, Bristol Myers is projecting adjusted earnings per share of , . More importantly, the revenue guidance is a significant beat. , . This is a meaningful upgrade that moves the goalposts.

The most critical part of this reset is the story behind the Eliquis guidance. Analysts had been braced for a sharp decline in the blood thinner's sales this year, anticipating a drop due to the lower price and its inclusion in . Instead, the company is projecting Eliquis revenue to grow in 2026. This defies the expectation gap. The rationale is a strategic pivot: the lower price helps the drug avoid U.S. Medicare penalties, which the company says will drive overall volume and revenue. In other words, the market was pricing in a hit to Eliquis, but management is guiding for it to become an "important driver of growth."

This guidance shift is a classic "beat and raise" scenario. The company delivered a solid quarter, but the real catalyst for the stock's move is the higher bar it has now set for the year ahead. The market's baseline for 2026 has been reset upward on both the top and bottom lines.

The Eliquis Catalyst: How Price Cuts Enable Growth

The most counter-intuitive part of Bristol Myers' guidance is the engine for Eliquis growth: a lower list price. The market had priced in a steep decline, expecting the drug's sales to fall significantly this year due to the lower price. . The mechanism is a direct financial incentive. By cutting the price, Eliquis avoids penalties from the U.S. Medicare program, a key driver of the . This strategic pivot turns a cost into a volume driver, allowing the drug to maintain or even expand its market share.

This is a classic case of an expectation gap. The market was focused on the headline price cut, missing the broader commercial calculus. Management's guidance implies the earlier pessimism about Eliquis was too severe. The lower price is not a sign of weakness but a calculated move to secure Medicare coverage and drive overall sales. In other words, the market was pricing in a hit, but the company is guiding for it to become an "important driver of growth."

This cost-cutting story extends beyond pricing. To support margins and fund the strategic shift, Bristol Myers executed a significant R&D reduction. . This move delivered tangible savings, . While trimming the pipeline carries long-term risks, the immediate impact was to bolster the bottom line and provide financial flexibility for this year's growth initiatives.

The bottom line is that the Eliquis catalyst works because the lower price is a direct financial incentive to avoid Medicare penalties, which drives sales. This guidance reset shows the market's expectation of a steep decline was too pessimistic. Combined with aggressive cost control, the setup for 2026 is one of managed expense and strategic pricing, not the headwinds many had feared.

Stock Reaction & Market Sentiment: Is the Good News Priced In?

The stock's move tells the real story. Bristol Myers shares are up , a powerful rally that suggests the market has already discounted the strong Q4 beat and the subsequent guidance reset. This isn't a "buy the rumor" pop; it's a sustained climb that implies the positive news has been fully priced in.

Yet, the longer-term view reveals a more cautious sentiment. Over the last 12 months, the stock is essentially flat, . This pattern points to a classic "sell the news" dynamic. The initial post-earnings pop was followed by a period of consolidation, as investors took profits and digested the new, higher expectations for 2026.

The guidance reset has created a new expectation gap. The company has raised the bar significantly, setting a new baseline for performance. The market now needs to see Bristol Myers execute flawlessly to meet that elevated target. Any stumble in 2026-whether from the Eliquis growth story faltering or other business lines missing-could trigger a sharp valuation reset. The stock's recent strength means there's little margin for error.

The bottom line is that the good news is priced in. The 23% three-month gain shows the market has embraced the beat-and-raise narrative. But the flat 12-month performance and the heightened guidance bar mean the stock is now in a vulnerable position. The setup is one of high expectations, where the next quarter's results will be scrutinized for any sign of deviation from the new, optimistic path.